公开(公告)号：AU4751393A

公开(公告)日：1993-12-16

申请号：AU4751393

申请日：1993-09-21

Applicant: ABBOTT LAB

Inventor： SCHOENLEBER ROBERT W ,  KEBABIAN JOHN W ,  MARTIN YVONNE C ,  DENINNO MICHAEL P ,  PERNER RICHARD J ,  STOUT DAVID M ,  HSIAO CHI-NUNG W

IPC: A61K31/135 ,  A61K31/35 ,  A61K31/40 ,  A61K31/535 ,  C07C215/52 ,  C07C217/60 ,  C07C219/28 ,  C07C237/08 ,  C07C271/16 ,  C07C271/44 ,  C07C271/58 ,  C07C309/65 ,  C07C323/60 ,  C07D207/08 ,  C07D207/16 ,  C07D209/44 ,  C07D221/10 ,  C07D221/20 ,  C07D311/76 ,  C07D311/96 ,  C07D319/20 ,  C07D335/06 ,  C07D405/04 ,  C07D405/06 ,  C07D405/12 ,  C07D407/10 ,  C07D493/10 ,  C07K5/06

公开(公告)号：ES2086405T3

公开(公告)日：1996-07-01

申请号：ES90909264

申请日：1990-05-22

Applicant: ABBOTT LAB

Inventor： SCHOENLEBER ROBERT W ,  KEBABIAN JOHN W ,  MARTIN YVONNE C ,  DENINNO MICHAEL P ,  PERNER RICHARD J ,  STOUT DAVID M

IPC: A61K31/13 ,  A61K31/135 ,  A61K31/16 ,  A61K31/335 ,  A61K31/40 ,  A61K31/403 ,  A61K31/404 ,  A61K38/00 ,  A61P9/00 ,  A61P25/00 ,  A61P25/18 ,  A61P25/30 ,  C07C41/02 ,  C07C215/48 ,  C07C215/64 ,  C07C217/56 ,  C07C217/74 ,  C07C219/28 ,  C07C233/18 ,  C07C237/08 ,  C07C271/16 ,  C07C271/44 ,  C07C309/65 ,  C07C323/60 ,  C07D207/08 ,  C07D209/08 ,  C07D209/62 ,  C07D221/06 ,  C07D221/10 ,  C07D221/20 ,  C07D311/76 ,  C07D311/78 ,  C07D311/96 ,  C07D313/08 ,  C07D405/04 ,  C07D405/06 ,  C07D405/12 ,  C07D407/04 ,  C07D407/12 ,  C07D493/10 ,  C07K5/06 ,  C07D409/04 ,  C07D311/74 ,  C07D487/00 ,  C07D209/56 ,  C07D211/00 ,  C07C69/76 ,  A01N43/32 ,  A01N43/16 ,  A01N43/42 ,  A01N43/62

Abstract: Novel compounds which are selective dopamine agonists are useful for treating disorders characterized by abnormal dopamine levels, such as Parkinson's Disease, as well as cardiovascular disorders.

公开(公告)号：AT134373T

公开(公告)日：1996-03-15

申请号：AT90909264

申请日：1990-05-22

Applicant: ABBOTT LAB

Inventor： SCHOENLEBER ROBERT W ,  KEBABIAN JOHN W ,  MARTIN YVONNE C ,  DENINNO MICHAEL P ,  PERNER RICHARD J ,  STOUT DAVID M ,  HSIAO CHI-NUNG W ,  DIDOMENICO STANLEY JR ,  DEBERNARDIS JOHN F ,  BASHA FATIMA Z ,  MEYER MICHEAL D ,  DE BISWANATH ,  EHRLICH PAUL P ,  CAMPBELL JAMES R ,  MORTON HOWARD E ,  LIJEWSKI LINDA M

IPC: A61K31/13 ,  A61K31/135 ,  A61K31/16 ,  A61K31/335 ,  A61K31/40 ,  A61K31/403 ,  A61K31/404 ,  A61K38/00 ,  A61P9/00 ,  A61P25/00 ,  A61P25/18 ,  A61P25/30 ,  C07C41/02 ,  C07C215/48 ,  C07C215/64 ,  C07C217/56 ,  C07C217/74 ,  C07C219/28 ,  C07C233/18 ,  C07C237/08 ,  C07C271/16 ,  C07C271/44 ,  C07C309/65 ,  C07C323/60 ,  C07D207/08 ,  C07D209/08 ,  C07D209/62 ,  C07D221/06 ,  C07D221/10 ,  C07D221/20 ,  C07D311/76 ,  C07D311/78 ,  C07D311/96 ,  C07D313/08 ,  C07D405/04 ,  C07D405/06 ,  C07D405/12 ,  C07D407/04 ,  C07D407/12 ,  C07D493/10 ,  C07K5/06 ,  C07D409/04 ,  C07D311/74 ,  C07D487/00 ,  C07D209/56 ,  C07D211/00 ,  C07C69/76 ,  A01N43/32

Abstract: Novel compounds which are selective dopamine agonists are useful for treating disorders characterized by abnormal dopamine levels, such as Parkinson's Disease, as well as cardiovascular disorders.

公开(公告)号：NZ233847A

公开(公告)日：1992-08-26

申请号：NZ23384790

申请日：1990-05-29

Applicant: ABBOTT LAB

Inventor： SCHOENLEBER ROBERT W ,  KEBABIAN JOHN W ,  MARTIN YVONNE C ,  DENINNO MICHAEL P ,  PERNER RICHARD J ,  STOUT DAVID M ,  CHI-NUNG W HSIAO ,  DIDOMENICO STANLEY ,  DEBERNARDIS JOHN F ,  BASHA FATIMA Z ,  MEYER MICHAEL D ,  DE BISWANATH ,  EHRLICH PAUL P ,  CAMPBELL

IPC: A61K31/13 ,  A61K31/135 ,  A61K31/16 ,  A61K31/335 ,  A61K31/40 ,  A61K31/403 ,  A61K31/404 ,  A61K38/00 ,  A61P9/00 ,  A61P25/00 ,  A61P25/18 ,  A61P25/30 ,  C07C41/02 ,  C07C215/48 ,  C07C215/64 ,  C07C217/56 ,  C07C217/74 ,  C07C219/28 ,  C07C233/18 ,  C07C237/08 ,  C07C271/16 ,  C07C271/44 ,  C07C309/65 ,  C07C323/60 ,  C07D207/08 ,  C07D209/08 ,  C07D209/62 ,  C07D221/06 ,  C07D221/10 ,  C07D221/20 ,  C07D311/76 ,  C07D311/78 ,  C07D311/96 ,  C07D313/08 ,  C07D405/04 ,  C07D405/06 ,  C07D405/12 ,  C07D407/04 ,  C07D407/12 ,  C07D493/10 ,  C07K5/06 ,  C07C215/50 ,  C07C215/52 ,  C07D493/04 ,  C07D335/06 ,  A61K31/22 ,  A61K31/35 ,  A61K31/38 ,  A61K31/445

Abstract: Novel compounds which are selective dopamine agonists are useful for treating disorders characterized by abnormal dopamine levels, such as Parkinson's Disease, as well as cardiovascular disorders.

公开(公告)号：DK0474767T3

公开(公告)日：1996-07-15

申请号：DK90909264

申请日：1990-05-22

Applicant: ABBOTT LAB

Inventor： DEBERNARDIS JOHN F ,  DE BISWANATH ,  SCHOENLEBER ROBERT W ,  KEBABIAN JOHN W ,  MARTIN YVONNE C ,  DENINNO MICHAEL P ,  PERNER RICHARD J ,  STOUT DAVID M ,  HSIAO CHI-NUNG W ,  DIDOMENICO STANLEY JR ,  BASHA FATIMA Z ,  MEYER MICHEAL D ,  EHRLICH PAUL P ,  CAMPBELL JAMES R ,  MORTON HOWARD E ,  LIJEWSKI LINDA M

IPC: A61K31/13 ,  A61K31/135 ,  A61K31/16 ,  A61K31/335 ,  A61K31/40 ,  A61K31/403 ,  A61K31/404 ,  A61K38/00 ,  A61P9/00 ,  A61P25/00 ,  A61P25/18 ,  A61P25/30 ,  C07C41/02 ,  C07C215/48 ,  C07C215/64 ,  C07C217/56 ,  C07C217/74 ,  C07C219/28 ,  C07C233/18 ,  C07C237/08 ,  C07C271/16 ,  C07C271/44 ,  C07C309/65 ,  C07C323/60 ,  C07D207/08 ,  C07D209/08 ,  C07D209/62 ,  C07D221/06 ,  C07D221/10 ,  C07D221/20 ,  C07D311/76 ,  C07D311/78 ,  C07D311/96 ,  C07D313/08 ,  C07D405/04 ,  C07D405/06 ,  C07D405/12 ,  C07D407/04 ,  C07D407/12 ,  C07D493/10 ,  C07K5/06 ,  C07D409/04 ,  A01N43/00 ,  A01N33/00 ,  A61K31/395 ,  A61K31/235 ,  C07D209/56 ,  C07D211/00 ,  C07D311/74 ,  C07C69/76 ,  C07D487/00

Abstract: Novel compounds which are selective dopamine agonists are useful for treating disorders characterized by abnormal dopamine levels, such as Parkinson's Disease, as well as cardiovascular disorders.

公开(公告)号：AU655898B2

公开(公告)日：1995-01-12

申请号：AU4751393

申请日：1993-09-21

Applicant: ABBOTT LAB

Inventor： SCHOENLEBER ROBERT W ,  KEBABIAN JOHN W ,  MARTIN YVONNE C ,  DENINNO MICHAEL P ,  PERNER RICHARD J ,  STOUT DAVID M ,  HSIAO CHI-NUNG W

IPC: A61K31/135 ,  A61K31/35 ,  A61K31/40 ,  A61K31/535 ,  C07C215/52 ,  C07C217/60 ,  C07C219/28 ,  C07C237/08 ,  C07C271/16 ,  C07C271/44 ,  C07C271/58 ,  C07C309/65 ,  C07C323/60 ,  C07D207/08 ,  C07D207/16 ,  C07D209/44 ,  C07D221/10 ,  C07D221/20 ,  C07D311/76 ,  C07D311/96 ,  C07D319/20 ,  C07D335/06 ,  C07D405/04 ,  C07D405/06 ,  C07D405/12 ,  C07D407/10 ,  C07D493/10 ,  C07K5/06

公开(公告)号：AU5818290A

公开(公告)日：1991-01-07

申请号：AU5818290

申请日：1990-05-22

Applicant: ABBOTT LAB

Inventor： SCHOENLEBER ROBERT W ,  DEBERNARDIS JOHN F ,  BASHA FATIMA Z ,  MEYER MICHEAL D ,  DE BISWANATH ,  KEBABIAN JOHN W ,  MARTIN YVONNE C ,  DENINNO MICHAEL P ,  PERNER RICHARD J ,  STOUT DAVID M ,  HSIAO CHI-NUNG W ,  DIDOMENICO STANLEY JR ,  EHRLICH PAUL P ,  CAMPBELL JAMES R ,  MORTON HOWARD E ,  LIJEWSKI LINDA M

IPC: A61K31/13 ,  A61K31/135 ,  A61K31/16 ,  A61K31/335 ,  A61K31/40 ,  A61K31/403 ,  A61K31/404 ,  A61K38/00 ,  A61P9/00 ,  A61P25/00 ,  A61P25/18 ,  A61P25/30 ,  C07C41/02 ,  C07C215/48 ,  C07C215/64 ,  C07C217/56 ,  C07C217/74 ,  C07C219/28 ,  C07C233/18 ,  C07C237/08 ,  C07C271/16 ,  C07C271/44 ,  C07C309/65 ,  C07C323/60 ,  C07D207/08 ,  C07D209/08 ,  C07D209/62 ,  C07D221/06 ,  C07D221/10 ,  C07D221/20 ,  C07D311/76 ,  C07D311/78 ,  C07D311/96 ,  C07D313/08 ,  C07D405/04 ,  C07D405/06 ,  C07D405/12 ,  C07D407/04 ,  C07D407/12 ,  C07D493/10 ,  C07K5/06 ,  C07D409/04 ,  C07D209/56 ,  C07D211/00 ,  C07C69/76 ,  A01N43/32 ,  A01N43/16 ,  A61K31/395 ,  A61K31/235 ,  C07D311/74 ,  C07D487/00 ,  A01N43/42 ,  A01N43/62 ,  A01N33/00

Abstract: Novel compounds which are selective dopamine agonists are useful for treating disorders characterized by abnormal dopamine levels, such as Parkinson's Disease, as well as cardiovascular disorders.

公开(公告)号：CA2056995A1

公开(公告)日：1990-12-01

申请号：CA2056995

申请日：1990-05-22

Applicant: ABBOTT LAB

Inventor： SCHOENLEBER ROBERT W ,  KEBABIAN JOHN W ,  MARTIN YVONNE C ,  DENINNO MICHAEL P ,  PERNER RICHARD J ,  STOUT DAVID M ,  HSIAO CHI-NUNG W ,  DIDOMENICO STANLEY JR ,  DEBERNARDIS JOHN F ,  BASHA FATIMA Z ,  MEYER MICHAEL D ,  DE BISWANATH ,  EHRLICH PAUL P ,  CAMPBELL JAMES R ,  MORTON HOWARD E ,  LIJEWSKI LINDA M

IPC: A61K31/13 ,  A61K31/135 ,  A61K31/16 ,  A61K31/335 ,  A61K31/40 ,  A61K31/403 ,  A61K31/404 ,  A61K38/00 ,  A61P9/00 ,  A61P25/00 ,  A61P25/18 ,  A61P25/30 ,  C07C41/02 ,  C07C215/48 ,  C07C215/64 ,  C07C217/56 ,  C07C217/74 ,  C07C219/28 ,  C07C233/18 ,  C07C237/08 ,  C07C271/16 ,  C07C271/44 ,  C07C309/65 ,  C07C323/60 ,  C07D207/08 ,  C07D209/08 ,  C07D209/62 ,  C07D221/06 ,  C07D221/10 ,  C07D221/20 ,  C07D311/76 ,  C07D311/78 ,  C07D311/96 ,  C07D313/08 ,  C07D405/04 ,  C07D405/06 ,  C07D405/12 ,  C07D407/04 ,  C07D407/12 ,  C07D493/10 ,  C07K5/06 ,  C07D493/04 ,  C07D413/06 ,  A61K31/35 ,  A61K31/395 ,  C07D209/60

Abstract: 2056995 9015056 PCTABS00002 Novel compounds are provided of formula (I), or a pharmaceutically acceptable salt, ester or amide thereof, wherein A is O, S, CHR2, CR2 or C when n is 0 and A and R6 taken together form a nitrogen-containing 5-, 6- or 7-membered ring, and n is zero or 1. The dotted lines represent optional double bonds. R1 is selected from hydrogen and a readily cleavable group. R2 is selected from hydrogen, alkyl, substituted alkyl, alkenyl and alkynyl. R3 is selected from alkyl, substituted alkyl, alkenyl, alkynyl, cycloalkyl, carbocyclic aryl, carbocyclic arylalkyl and heterocycle. R4 is selected from hydrogen and alkyl or, taken together with R3 and the carbon atom to which they are attached, forms a spirocycloalkyl ring of from 3 to 7 carbons. R5 is selected from hydrogen, alkyl and substituted alkyl or, taken together with R3 and the carbon atoms to which they are attached forms a cycloalkyl ring of from 5 to 7 carbons. R6 is selected from hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, carbocyclic arylalkyl, alkanoyl of from 1 to 8 carbons, amino acid and dipeptide or, taken together with A when A is C and when n is 0, forms a nitrogen-containing 5-, 6-, or 7-membered ring. R7 is hydrogen or alkyl or, taken together with R6 or R8, forms a nitrogen-containing 5-, 6- or 7-membered ring, provided that when R6 is carbocyclic arylalkyl, R7 is not alkyl. R8 is hydrogen or alkyl or, taken together with R6 or R7, forms a nitrogen-containing 5-, 6-, or 7-membered ring or, taken together with the catechol ring at the 8-position and the carbon atoms to which they are attached, forms a 5-, 6- or 7-membered ring. The compounds of the invention are useful for treating dopamine-related neurological, psychological and cardiovascular disorders as well as in the treatment of cognitive impairment, attention deficit disorder, and substance abuse and other addictive behavior disorders.